http://californiabiotechlaw.com Mon, 26 Sep 2011 01:58:02 +0000 http://backend.userland.com/rss092 en Now that President Obama signed the patent reform bill into law on Sept. 16, 2011, it is only fitting to ask whether the passage of this bill was a win for the biotech industry? According to Roy Zwahlen, manager of intellectual property and technology transfer policy at BIO, the answer is ... http://californiabiotechlaw.com/archives/biotech-legislative-developments/the-passage-of-patent-reform-is-this-really-a-win-for-the-biotech-industry/ Fourteen states filed suit yesterday to challenge the constitutionality of the health care reform bill. The states of Florida, Alabama, Colorado, Idaho, Louisiana, Michigan, Nebraska, Pennsylvania, South Carolina, South Dakota, Texas, Utah, and Washington joined together in a suit filed in Florida. Virginia filed its own suit separately. The crux of these suits ... http://californiabiotechlaw.com/archives/biotech-legislative-developments/fourteen-states-launch-constitutional-challenge-to-health-care-reform-bill/ Well, unless you have spent the last few weeks stranded on a desert island, you probably know that yesterday was the big health care vote.  As expected, the Democratic majority in the House passed the health care reform bill--despite the fact that the bill was vigorously opposed by a large ... http://californiabiotechlaw.com/archives/biotech-legislative-developments/biotech-industry-evaluates-anticipated-impact-of-health-care-reform/ Medicareer has named the California Biotech Law Blog to be on its list of Top 50 Biotech Blogs. The California Biotech Law Blog joins  a number of well-regarded publications, which also made the list such as the  In Vivo Blog and the  BioHealth Investor.  The list also includes a number of ... http://californiabiotechlaw.com/archives/biotech-blog-in-the-news/california-biotech-law-blog-named-to-list-of-top-50-biotech-blogs/ Billionaire Carl Icahn is at it again.  Icahn, who has a history of engineering board takeovers and initiating corporate sales at the corporations in which he invests, now has focused his efforts squarely on the Genzyme board. Various media outlets are reporting that Icahn plans to nominate four new board members, ... http://californiabiotechlaw.com/archives/biotech-industry-news/carl-icahn-makes-move-to-raid-genzyme-board/ I was recently interviewed by Clara Cottrell of TheScitechLawyer regarding the challenges of building a law firm and my advice for lawyers who are trying to build firms or even just simply build careers in these difficult economic times. To read the article in full, please click here: http://prinzlawoffice.com/wp-content/uploads/2010/01/scitechprofilekristieprinz1.pdf. http://californiabiotechlaw.com/archives/biotech-blog-in-the-news/thescitechlawyer-profiles-california-biotech-law-blogs-kristie-prinz/ I recently sat down with IP Society's Patrick Reilly to discuss intellectual property licensing and what start-ups seeking legal counsel need to know about intellectual property licensing.  The focus of the interview was on technology licensing, particularly in the software area, rather than biotechnology licensing, but I wanted to bring ... http://californiabiotechlaw.com/archives/biotech-blog-in-the-news/patrick-reilly-of-ip-society-interviews-california-biotech-law-blogs-kristie-prinz/ Technology Transfer Tactics recently interviewed me on the issue of whether poster presentations jeopardize a tech transfer office's commercialization efforts. I wanted to share the interview because the article raised some interesting questions.  Of course, universities have long been dealing with the challenges of having to reconcile the competing interests of ... http://californiabiotechlaw.com/archives/biotech-blog-in-the-news/kristie-prinz-interviewed-by-technology-transfer-tactics-on-issue-of-whether-poster-presentations-jeopardize-a-ttos-commercialization-efforts/ The Seventh Circuit decided last week in favor of the Wisconsin Alumni Research Foundation ("WARF") in its licensing dispute with Xenon Pharmaceuticals. As I stated in my Silicon Valley IP Licensing Blog posting on this case, I strongly agree with the outcome in this case and I view this decision as ... http://californiabiotechlaw.com/archives/biotech-deals/seventh-circuit-rules-in-favor-of-warf-in-licensing-dispute-with-xenon-pharmaceuticals-case/ Despite ongoing negotiations in the Senate and House throughout 2009, the new year is beginning with the SBIR reauthorization effort at a continued standstill. While Congress did successfully save the SBIR/STTR from extinction by implementing a series of five continuing resolutions ("CR") since the authorization expired back in September 2008, no ... http://californiabiotechlaw.com/archives/biotech-legislative-developments/sbir-reauthorization-effort-continues-to-be-at-standstill/